Yahoo Finance • 16 hours ago
Research and Development Expenses: $41.4 million for Q1 2025, up from $24.1 million in Q1 2024. General and Administrative Expenses: $14.1 million for Q1 2025, up from $10 million in Q1 2024. Net Loss: $45.6 million or $0.41 per share for... Full story
Yahoo Finance • 7 days ago
Eli Lilly (NYSE:LLY) shares surged around 14% in premarket trading Thursday after the company reported positive Phase 3 trial results for orforglipron, its once-daily oral GLP-1 drug for type 2 diabetes. Warning! GuruFocus has detected 6... Full story
Yahoo Finance • 7 days ago
Equity markets have had a rough go of it this year due to President Trump's macroeconomic policies. Though it can be challenging to navigate this environment, one way to make the best of it is to look for terrific stocks to invest in while... Full story
Yahoo Finance • 9 days ago
No one ever claimed investing in the biotech industry was a smooth ride, but for shareholders of Viking Therapeutics(NASDAQ: VKTX), the turbulence has been extremely challenging thus far. The stock is down 71% over the past year, amid ongo... Full story
Yahoo Finance • 10 days ago
Bad news for Pfizer (NYSE: PFE) turned into good news for Eli Lilly (NYSE: LLY), Novo Nordisk(NYSE: NVO), and Viking Therapeutics(NASDAQ: VKTX) Monday morning, each of which is rising on Pfizer's latest product announcement. Early this mo... Full story
Yahoo Finance • 12 days ago
When the stock market is as turbulent as it is these days, it's easy to forget the times when things are decidedly more cheery. However, sell-offs present great opportunities to buy stocks with significant upside potential. Three Motley F... Full story
Yahoo Finance • last month
We recently published a list of 10 Stocks Skyrocketing Today. In this article, we are going to take a look at where Viking Therapeutics Inc. (NASDAQ:VKTX) stands against other stocks that are skyrocketing today. The stock market ended mix... Full story
Yahoo Finance • 2 months ago
AbbVie inked a licensing deal Monday worth up to $2.23 billion for an amylin-targeting obesity treatment from Denmark-based Gubra A/S. Continue Reading View Comments... Full story
Yahoo Finance • 2 months ago
We recently published a list of 10 Stocks Stand Strong Amid Cautious Market Environment. In this article, we are going to take a look at where Viking Therapeutics, Inc. (NASDAQ:VKTX) stands against stocks that stand strong amid cautious ma... Full story
Yahoo Finance • 3 months ago
We recently published a list of 15 Stocks That Took a Nosedive in January. In this article, we are going to take a look at where Viking Therapeutics, Inc. (NASDAQ:VKTX) stands against other stocks that took a nosedive in January. Historic... Full story
Yahoo Finance • 3 months ago
Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second presidency. Continue reading View comments... Full story
Yahoo Finance • 6 months ago
Madrigal stock catapulted again Friday after Novo Nordisk published not "game-changing" results for its MASH treatment. Continue reading View comments... Full story
Yahoo Finance • 7 months ago
We recently compiled a list of the 10 Best Performing Small-Cap Stocks in 2024. In this article, we will look at where Viking Therapeutics Inc. (NASDAQ:VKTX) ranks among the best-performing small-cap stocks in 2024. The Case for Small Cap... Full story
Yahoo Finance • 8 months ago
Nvidia(NASDAQ: NVDA) is a tough one to beat when it comes to share-price performance. The technology giant has seen its shares soar 2,500% over the past five years, and this year, it's heading for a 118% increase. There's a good reason fo... Full story
Yahoo Finance • 8 months ago
Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here. Small-cap stocks were unable to sustain the po... Full story
Yahoo Finance • 8 months ago
Shares of Viking Therapeutics(NASDAQ: VKTX), a clinical-stage drugmaker working on metabolic treatments, have tripled in value this year. Despite the huge run-up, analysts who follow the company think it has heaps more upside. The average... Full story
Yahoo Finance • 8 months ago
On August 19, 2024, J Singleton, Director at Viking Therapeutics Inc (NASDAQ:VKTX), executed a sale of 16,000 shares of the company. The transaction was documented in a recent SEC Filing. Following this transaction, the insider now owns 9,... Full story
Yahoo Finance • 8 months ago
We recently compiled a list of the 7 Best Diabetes Stocks To Buy Now.In this article, we are going to take a look at where Viking Therapeutics, Inc. (NASDAQ:VKTX) stands against the other diabetes stocks. According to the WHO, approximate... Full story
Yahoo Finance • 9 months ago
Viking Therapeutics(NASDAQ: VKTX) just gave shareholders a few more reasons to be excited for the future. With its shares soaring by a stunning 34% on July 25 thanks to second-quarter earnings, the bull thesis for its continued outperforma... Full story
Yahoo Finance • 9 months ago
If you're an investor focused on growth, you may have spent a fair share of your time at least watching Nvidia (NASDAQ: NVDA) stock in recent times -- even if you haven't jumped in to invest in this high-flyer. Nvidia dominates the artific... Full story